Clinical Research

South Shore Neurologic Associates Clinical Research Department has focused on bringing groundbreaking medication opportunities to patients in need. The clinical trials are designed to help evaluate medications & devices prior to FDA approval, as well as further evaluate post-approval medications. Bringing high-tech research to our community provides opportunities that allow our patients access to medications & devices that are on the cutting edge of science opening new avenues for those who are unable to obtain relief from other therapies. We have participated in many clinical trials for Multiple Sclerosis, Parkinson's disease, Huntington's disease, and compassionate access treatments for ALS.

Medical Staff:

Lori Fafard, RN, BSN, CNRN, MSCN, CCRP
Laura Graffitti, RN, BSN, CNRN, MSCN, CCRP
Kristen Capriola, RN, BSN, SC
Stephanie Galarza, SC
Erin Vacey, Clinical Assistant

Active Studies as of 02/26/2016 

Study Name

Study Coordinator(s)

Phone Extension

Study Population

Acorda Dalf-PS-1016 Stephanie, Kristen 2247, 2206 Double-Blind, placebo-controlled, Parallel group study to evaluate the efficacy and safety of two dose strengths of dalfampridine extended release tablets for treatment of stable walking deficits in post-ischemic stroke patients ages 18+ and had their stroke >6months ago
Alkermes ALK8700-A301 Kristen, Stephanie 2206, 2247 Phase 3 open label study to evaluate the long-term safety and tolerability of ALKS 8700 in adults with RRMS. Oral disease modifying therapy
Assess CFTY720D2312 Lori 2205 RRMS; New start Gilenya
Biogen 109MS414 Laura 2207 Multicenter, Double blind, placebo controlled study of Montelukast on GI Tolerability in patients with RRMS on Tecfidera. Ages 18+
Biorasi/Osmotica OS320-3005/6 Stephanie, Lori, Kristen 2247,2205, 2206 Randomized placebo-controlled, double blind, 16/26 week study to evaluate the efficacy and safety of Amantadine extended release tablets in PD with Levodopa-induced Dyskenesias
Chugai NMO/NMOSD Lori 2205 NMO: MULTI-CENTER, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as MONO-THERAPY in patients with neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD)
ESTEEM 109-MS-401 Laura 2207 RRMS; observational new start Tecfidera LT benefit; determine reasons for SAE's, DMTs routine prescription utilization & efficacy
PASSAGE CFTY720D2403 Laura 2207 Observational study new start all MS DMTs
CIDP CFTY72012201 Lori 2205 CIDP subjects
RESPOND 109MS404 Laura 2207 12 month observational Tecfidera
WILKENS Lori, Laura, Erin 2205, 2207, 2246 Neurotrax validation study MS pt's 95 subjects (15 of 95 normal controls)

Locations this service is offered at:

77 Medford Avenue (Route 112)
Patchogue, NY 11772

Tel: 631-758-1910
Fax: 631-750-1014